Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluation of COVID-19 vaccination strategies with a delayed second dose

View ORCID ProfileSeyed M. Moghadas, Thomas N. Vilches, View ORCID ProfileKevin Zhang, Shokoofeh Nourbakhsh, Pratha Sah, Meagan C. Fitzpatrick, Alison P. Galvani
doi: https://doi.org/10.1101/2021.01.27.21250619
Seyed M. Moghadas
1Agent-Based Modelling Laboratory, York University, Toronto, Ontario, M3J 1P3 Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Seyed M. Moghadas
  • For correspondence: moghadas@yorku.ca
Thomas N. Vilches
2Institute of Mathematics, Statistics and Scientific Computing, University of Campinas, Campinas SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Zhang
3Faculty of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8 Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin Zhang
Shokoofeh Nourbakhsh
1Agent-Based Modelling Laboratory, York University, Toronto, Ontario, M3J 1P3 Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pratha Sah
4Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meagan C. Fitzpatrick
4Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
5Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 W Baltimore St, Baltimore, MD 21201 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison P. Galvani
4Center for Infectious Disease Modeling and Analysis (CIDMA), Yale School of Public Health, New Haven, Connecticut, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

COVID-19 vaccines currently approved in the United States require two doses, administered three to four weeks apart. Constraints in vaccine supply and distribution capacity, together with the rise of COVID-19 cases and hospitalizations, have sparked a policy debate on whether to vaccinate more individuals with the first dose of available vaccines and delay the second dose, or to continue with the recommended two-dose series as tested in clinical trials. We developed an agent-based model of COVID-19 transmission to compare the impact of these two vaccination strategies, while varying the temporal waning of vaccine efficacy against disease following the first dose, vaccine efficacy against infection, and the level of pre-existing immunity in the population. Our results show that for Moderna vaccines with 80% efficacy following the first dose, a delay of 9-12 weeks could enhance the program effectiveness and prevent additional infections, hospitalizations, and deaths, compared to a 4-week interval between the doses. However, for Pfizer-BioNTech vaccines with demonstrated efficacy of 52% after the first dose, there was no clear advantage for delaying the second dose beyond the 3-week tested schedule, unless the efficacy of the first dose did not wane over time. Our findings underscore the importance of quantifying the durability of vaccine-induced protection after the first dose as well as vaccine efficacy against infection in order to determine the optimal time interval between the two doses.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Canadian Institutes of Health Research [OV4-170643, COVID-19 Rapid Research]; São Paulo Research Foundation [18/24811-1]; the National Institutes of Health [1RO1AI151176-01; 1K01AI141576-01], and the National Science Foundation [RAPID 2027755; CCF-1918784].

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No ethics approval required.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The computational system and parameters are available under an open source license at: https://github.com/thomasvilches/delayed_dose.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 29, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of COVID-19 vaccination strategies with a delayed second dose
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation of COVID-19 vaccination strategies with a delayed second dose
Seyed M. Moghadas, Thomas N. Vilches, Kevin Zhang, Shokoofeh Nourbakhsh, Pratha Sah, Meagan C. Fitzpatrick, Alison P. Galvani
medRxiv 2021.01.27.21250619; doi: https://doi.org/10.1101/2021.01.27.21250619
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Evaluation of COVID-19 vaccination strategies with a delayed second dose
Seyed M. Moghadas, Thomas N. Vilches, Kevin Zhang, Shokoofeh Nourbakhsh, Pratha Sah, Meagan C. Fitzpatrick, Alison P. Galvani
medRxiv 2021.01.27.21250619; doi: https://doi.org/10.1101/2021.01.27.21250619

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (580)
  • Anesthesia (141)
  • Cardiovascular Medicine (1962)
  • Dentistry and Oral Medicine (253)
  • Dermatology (187)
  • Emergency Medicine (335)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (703)
  • Epidemiology (11123)
  • Forensic Medicine (8)
  • Gastroenterology (629)
  • Genetic and Genomic Medicine (3196)
  • Geriatric Medicine (310)
  • Health Economics (567)
  • Health Informatics (2049)
  • Health Policy (864)
  • Health Systems and Quality Improvement (789)
  • Hematology (310)
  • HIV/AIDS (685)
  • Infectious Diseases (except HIV/AIDS) (12742)
  • Intensive Care and Critical Care Medicine (708)
  • Medical Education (318)
  • Medical Ethics (92)
  • Nephrology (337)
  • Neurology (3004)
  • Nursing (165)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1561)
  • Ophthalmology (478)
  • Orthopedics (186)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (386)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2799)
  • Public and Global Health (5613)
  • Radiology and Imaging (1101)
  • Rehabilitation Medicine and Physical Therapy (637)
  • Respiratory Medicine (764)
  • Rheumatology (341)
  • Sexual and Reproductive Health (315)
  • Sports Medicine (289)
  • Surgery (348)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)